{
    "clinical_study": {
        "@rank": "95942", 
        "arm_group": {
            "arm_group_label": "Liraglutide", 
            "arm_group_type": "Experimental", 
            "description": "Liraglutide 0.6 mg/day subcutaneously."
        }, 
        "brief_summary": {
            "textblock": "The study investigates the effect of glucagon-like peptide receptor 1 agonist, liraglutide,\n      on insulin secretion. Study hypothesis: the effect of liraglutide on insulin release may\n      change after repeated administration.  The effect of liraglutide on insulin release will be\n      tested using graded glucose infusion test (GGIT) in healthy volunteers. GGIT will be\n      performed without medication and repeated 12 hours after first dose of liraglutide and after\n      3 weeks of treatment with liraglutide."
        }, 
        "brief_title": "Effect of Repeated Administration of Liraglutide on Insulinogenic Indices", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Weight 50-100 kg\n\n        Exclusion Criteria:\n\n          -  Chronic disease\n\n          -  Concomitant drug use\n\n          -  Pregnancy or lactation\n\n          -  Fasting glucose >6 mmol/L."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089256", 
            "org_study_id": "LI20/1101"
        }, 
        "intervention": {
            "arm_group_label": "Liraglutide", 
            "description": "Graded glucose infusion test  (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.\nGGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).", 
            "intervention_name": "Liraglutide", 
            "intervention_type": "Drug", 
            "other_name": "Victoza"
        }, 
        "intervention_browse": {
            "mesh_term": "Glucagon-Like Peptide 1"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "contact": {
                "email": "vallo.volke@ut.ee", 
                "last_name": "Vallo Volke, MD", 
                "phone": "7374338", 
                "phone_ext": "+372"
            }, 
            "facility": {
                "address": {
                    "city": "Tartu", 
                    "country": "Estonia"
                }, 
                "name": "Tartu University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Vallo Volke, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Tuuli Sedman, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Estonia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Repeated Administration of Liraglutide on Insulinogenic Indices", 
        "overall_contact": {
            "email": "vallo.volke@ut.ee", 
            "last_name": "Vallo Volke, MD", 
            "phone": "7274338", 
            "phone_ext": "+372"
        }, 
        "overall_official": {
            "affiliation": "Tartu University", 
            "last_name": "Vallo Volke, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Estonia: State Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Graded glucose infusion test will be used to create insulin secretion rate- plasma glucose curve. The primary outcome is the change of the slope of the curve from baseline  after acute administration of liraglutide compared to the repeated administration (after 3-weeks of treatment).", 
            "measure": "Change in the glucose-sensitivity of the beta cells", 
            "safety_issue": "No", 
            "time_frame": "baseline, first dose, after 3-weeks on treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089256"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Tartu", 
            "investigator_full_name": "Vallo Volke", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "change in ACTH/cortisol levels and renin / aldosterone levels after acute and repeated administration of liraglutide.", 
            "measure": "Effects on adrenal hormones", 
            "safety_issue": "No", 
            "time_frame": "baseline, acute administration, 3 weeks"
        }, 
        "source": "University of Tartu", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Tartu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}